Web11 mei 2024 · Ionpath has been developing multiplexed ion beam imaging (MIBI) technology for quantitative protein imaging with high sensitivity and subcellular resolution down to 350 nanometers. It uses metal-conjugated antibodies to tag proteins of interest and MIBI to ionize samples for mass spectrometry analysis. WebMIBI™ technology (Multiplexed Ion Beam Imaging) uses Secondary-Ion Mass Spectrometry (SIMS), a type of mass spectrometry traditionally used in the semiconductor industry, to …
Ionpath
Web20 aug. 2024 · MENLO PARK, Calif., Aug. 20, 2024 /PRNewswire/ -- IONpath, Inc., the leader in high-definition spatial proteomics, today announced the appointment of Sander Gubbens, PhD, as its new CEO. Dr.... Web19 feb. 2024 · Fluidigm sued IonPathin September 2024, alleging that the company had infringed two patents covering its mass cytometry technology and had interfered in its contractual relations. In January 2024, the court dismissedFluidigm's interference claims but left open the infringement claims. rbhh products
Ionpath Roadmap - YouTube
WebInvesting in Breakthroughs. We invest across sectors, stages and technologies. We operate as one team, working together to identify and evaluate investment opportunities and to … Web6 okt. 2024 · Oct 6, 2024. The Ionpath team is excited to announce a new funding round that will directly support our customers, and the continued expansion of our technology, … WebIONpath's MIBIscope multiplexed ion beam imaging system (MIBI) allows researchers to image 40+ biomarkers in tissue with high resolution, high sensitivity, and high throughput. MIBI utilizes secondary ion mass spectrometry (SIMS) to detect metal-tagged antibodies that correspond to immune markers and tumor cells within the tumor microenvironment. rbhh specialist care